Abstract 1736P
Background
Young adult lung cancer's socioeconomic and clinical implications make it a unique disease. However, in Bangladesh, the status and features of early-onset lung cancer are not well understood. This study aimed to investigate the socio-demographic status and clinical characteristics of lung cancer in young adults in Bangladesh.
Methods
A retrospective review of patients with lung cancer was performed in our institute from January 2018 and December 2022. Young adults were defined as individuals between 18 and 45 years old. Demographic, clinicopathological and prognostic data were systematically analysed.
Results
Of the 6310 patients, 819 (12.98%) were young adults, and 780 were included in this study. The average age of young adult lung cancer patients was 38.92 years, and the average BMI was 20.46. Of all adult lung cancer patients, 29.49% were female, 58.97% were illiterate, and 87.56% had poor or below-average economic status. Among young adults, 23.08% did not use tobacco, while 41.41% had more than one tobacco-related habit. 33.52% of young patients with right-sided dominant lung cancer had a previous respiratory disease. At the time of presentation, 43.85% of patients had a score of ≥2 on the ECOG scale, and 33.52% had comorbidities, with hypertension being the most frequent (37.36%) and DM (33%) being the second most common. Adenocarcinoma was the most prevalent subtype (58.97%), followed by squamous (24.74%), small cell varieties with undifferentiated (14.74%), and others like sarcoma and mesothelioma. Stage 4 was diagnosed in 28.46% of patients, and the most frequent metastatic site was the lung (14.42%), followed by the pleura (12.5%) and the liver (11.06%). Young lung cancer patients in Bangladesh significantly differed from older adults regarding higher BMI, lower education, more female patients, fewer tobacco users, adenocarcinoma, and different metastatic sites (p 0.05).
Conclusions
The high prevalence of young adult lung cancer in Bangladesh necessitates specialized attention to this vulnerable group during treatment. These patients face unique challenges, making the management of their cancer complex and resulting in poor outcomes. A personalized and comprehensive approach is essential to manage young lung cancer effectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23